Abstract
Menopausal hormone therapy currently has no evidence-based role in the primary or secondary prevention of cardiovascular disease in women. Repeat analysis of the observational data that corrected for socioeconomic status, educational level, and coronary risk factors; as well as information from randomized clinical trials of menopausal hormone therapy both for healthy women and for women with established coronary heart disease and stroke support this statement. This approach is corroborated by recommendations from the US Food and Drug Administration and the recently released Guidelines for Cardiovascular Prevention for Women of the American Heart Association. The latter Guidelines display the lifestyle and pharmacologic interventions that are appropriate for cardiovascular disease risk reduction for women.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wenger NK. Menopausal hormone therapy. Is there evidence for cardiac protection? In: Shaw LJ, Redberg RF, eds. Contemporary Cardiology: Coronary Disease in Women: Evidence-Based Diagnosis and Treatment. Totowa, NJ: Humana Press, 2003: 321–348.
NK Wenger (2003) ArticleTitleCoronary heart disease: the female heart is vulnerable. Prog Cardiovasc Dis 46 199–229
E Barrett-Connor D Grady (1998) ArticleTitleHormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 19 55–72
LL Humphrey BK Chan HC Sox (2002) ArticleTitlePostmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 137 273–284
S Hulley D Grady T Bush et al. (1998) ArticleTitleFor the Heart and Estrogen/progestin Replacement Study (HERS) Research Group.Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 605–613
SC Clarke J Kelleher H Lloyd-Jones et al. (2002) ArticleTitleA study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study. BJOG: An Int J Obstetr Gynaecol 109 1056–1062
DM Herrington DM Reboussin KB Brosnihan et al. (2000) ArticleTitleEffects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343 522–529
CM Viscoli LM Brass WN Kernan et al. (2001) ArticleTitleA clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345 1243–1249 Occurrence Handle10.1056/NEJMoa010534 Occurrence Handle1:CAS:528:DC%2BD3MXnslOnt7Y%3D Occurrence Handle11680444
D Grady D Herrington V Bittner et al. (2002) ArticleTitleFor the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 49–57
group for the women’s health initiative investigators Writing (2002) ArticleTitleRisks and benefits of estrogen plus progestin in healthy postmenopausal women.Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288 321–333 Occurrence Handle1:CAS:528:DC%2BD38Xltlegs7k%3D
JE Manson J Hsia KC Johnson et al. (2003) ArticleTitleFor the Women’s health initiative investigators.estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 523–534
SA Shumaker C Legault SR Rapp et al. (2003) ArticleTitleFor the WHIMS Investigators.Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 289 2651–2662 Occurrence Handle1:CAS:528:DC%2BD3sXktVCqs7w%3D Occurrence Handle12771112
SR Rapp MA Espeland SA Shumaker et al. (2003) ArticleTitlefor the WHIMS Investigators.Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 289 2663–2672
DD Waters EL Alderman J Hsia et al. (2002) ArticleTitleEffects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 288 2432–2440
InstitutionalAuthorNameThe ESPRIT Team. (2002) ArticleTitleOestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 360 2001–2008
HN Hodis WJ Mack SP Azen et al. (2003) ArticleTitlefor the Women’s Estrogen–Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group.Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 349 535–545
http: //www.whi.org/updates/advisory_ea_physicians.htm. Women’s Health Initiative. Accessed March 30, 2004.
US Food and Drug Administration. Center for Drug Evaluation and Research. Estrogen and estrogen with progestin therapies for postmenopausal women. Available at www. fda. gov/cder/drug/infopage/estrogens_progestins/default. htm. Accessed March 3, 2003.
www.fda.gov/bbs/topics/NEWS/2004/NEW01022.html. Accessed February 19, 2004
L Mosca LJ Appel EJ Benjamin et al. (2004) ArticleTitleEvidence-based guidelines for cardiovascular disease prevention in women. Circulation 109 672–692
Author information
Authors and Affiliations
Additional information
Updated from a presentation at the Seventh International Conference on Geriatric Nephrology and Urology, Atlanta, GA, October 10, 2003.
Rights and permissions
About this article
Cite this article
Wenger, N.K. Menopausal hormone therapy: Is there evidence for cardiac protection?. Int Urol Nephrol 36, 617–623 (2004). https://doi.org/10.1007/s11255-004-6197-8
Issue Date:
DOI: https://doi.org/10.1007/s11255-004-6197-8